MDI Therapeutics Celebrated Launch of Startup with Bell Ringing
On Wednesday, June 13, 2023, MDI Therapeutics celebrated the launch of its status as a startup company with a bell ringing held at the Innovation Partnerships office. MDI Therapeutics was founded by Daniel Lawrence and other key members of the team—including MDI Therapeutics President & CEO Stephen Benoit, Corey Emal, Joe Su and Duane Day—were in attendance for the ringing of the bell.
MDI Therapeutics is a pharmaceutical company developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders. The Company was founded on key enabling technologies developed at the University of Michigan. MDI’s lead program is a first-in-class orally available plasminogen activator inhibitor (PAI-1) inhibitor.
More than 30 years of research and development has gone into the launch of MDI Therapeutics. The work and effort has been a joint venture with Eastern Michigan University and the team received research funding from MTRAC Life Sciences Innovation Hub as well as NIH SBIR funding.
“The Innovation Partnerships team has been instrumental in MDI Therapeutics coming to fruition,” said MDI Therapeutics founder Daniel Lawrence. “The group of people we’ve had the opportunity to work with have been champions for us since the beginning and we will always be grateful to have them on our team.”
MDI Therapeutics is moving toward Phase I clinical trials.
To learn more about MDI Therapeutics, visit: https://mditherapeutics.com/.